Announcement on Obtaining Approval for Lanthanum Carbonate Chemical API Listing Application

Rundu Co., Ltd.·July 21, 2026·2 pages

✨ AI Summary

Zhuhai Rundu Pharmaceutical Co., Ltd. announced it has received approval from the NMPA for its Lanthanum Carbonate chemical API listing application. This approval expands the company's product portfolio in chronic disease treatment, enhancing market competitiveness and positively impacting future performance. The company notes potential market uncertainties due to policy and market changes.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 002923

Securities Abbreviation: Rundu Shares

Announcement Number: 2026-051

Zhuhai Rundu Pharmaceutical Co., Ltd.

Announcement on Obtaining Approval for Lanthanum Carbonate Chemical API Listing Application

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from false records, misleading statements, or material omissions.

Zhuhai Rundu Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") recently received the "Chemical API Listing Application Approval Notice" for Lanthanum Carbonate (hereinafter referred to as "this product") issued by the National Medical Products Administration. The relevant situation is hereby announced as follows:

I. Basic Drug Information

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.